

DAVID H. HOWARD

Department of Health Policy and Management
Rollins School of Public Health
Emory University
1518 Clifton Road, NE, Room 656
Atlanta, GA 30322

404-727-3907
404-727-9198 (fax)
david.howard@emory.edu
<https://scholarblogs.emory.edu/davidhoward/>
This version: October 2023

EMPLOYMENT

Faculty, Department of Health Policy and Management, Rollins School of Public Health, Emory University. 2000-Present.

Core Member, Cancer Control and Population Sciences Program, Winship Cancer Institute, Emory University School of Medicine.

EDUCATION

Harvard University, Ph.D. in Health Policy, economics concentration, 2000.

Vassar College, B.A. Major in economics with a minor in math. 1994.

ADVISORY COMMITTEES AND OTHER PROFESSIONAL SERVICE

Editor. *International Journal of Health Economics and Management*. 2016-Present.

Affiliate. NBER's Center for Aging and Health. 2021-

External reviewer. Congressional Budget Office, *How Does CBO Analyze Approaches to Improve Health Through Prevention?* 2020.

Medicare Evidence Development & Coverage Advisory Committee. Centers for Medicare & Medicaid Services. 2013-2016.

Chair, Scientific and Technical Advisory Board, National Living Donor Assistance Center, American Society of Transplant Surgeons and the University of Michigan. 2007-2016.

Scientific Registry of Transplant Recipients Technical Advisory Committee – Program-Specific Reports (PSR) Methodology Subcommittee. 2013-2014.

External reviewer, Department of Health and Human Services, Cooperative Agreements to Support Establishment of the Affordable Care Act's Health Insurance Exchanges. 2013.

Scientific and Technical Advisory Committee, Scientific Registry of Transplant Recipients. 2008-2012.

Editorial Board, *Medical Decision Making*. 2009-2011.

Steering Committee, Global Advisory on Antibiotic Resistance Data. 2005-2007.

Committee on Increasing Rates of Organ Donation, Institute of Medicine, National Academy of Sciences. 2005-2006.

21st Century Beneficiary Expert Panel, Medicare Payment Advisory Commission (MEDPAC). 2006.

Advisory Panel on Determinants of Organ Donation, Division of Transplantation, Department of Health and Human Services. 2001.

SCHOOL SERVICE

Director, Doctoral Program in Health Policy. Emory University. 2006-2009, 2020-Present.

Member, Emory Faculty Senate, 2019-2022.

Member, Tenure & Promotion Advisory Committee, Emory University. 2020-2022.

Member, Appointments, Promotions, and Tenure Committee, Rollins School of Public Health. 2009-2020.

Chair, Career Services Advisory Committee. 2011-2014.

Chair, Shepard Award Committee. 2002-2013.

ARTICLES

Health Policy and Economics

1. Howard DH, David G. For-profit hospitals and excess inpatient admissions from the emergency department. *Health Services Research* Forthcoming.
2. Howard DH, Hockenberry J. Medicare fee reductions and the overuse of intensity modulated radiotherapy. *Health Services Research* 2021;56(4):626-634.
3. Rao B, Dickert N, Merchant FM, Matlock, DD, Howard DH. Shared decision-making for implantable cardioverter-defibrillators: policy goals, metrics, and challenges. *Journal of Law Medicine and Ethics* 2021;49(4):622-629.
4. Howard DH, McCarthy I. Deterrence effects of antifraud and abuse enforcement in health care. *Journal of Health Economics* 2021;75:102405.
5. Howard DH, Desai N. False claims act investigations of unnecessary percutaneous coronary interventions. *JAMA Internal Medicine* 2020;180(11):1534-1536.
6. Graetz I, Yarbrough CR, Hu X, Howard DH. Association of mandatory-access prescription drug monitoring programs with opioid prescriptions among Medicare patients treated by a medical or hematologic oncologist. *JAMA Oncology* 2020:1102-1103.
7. Howard DH, Torres M. Alternative payment for radiation oncology. *Journal of the American Medical Association* 2019;322(19):1859-1860.
8. Howard DH. False Claims Act liability for overtreatment. *Journal of Health Politics, Policy and Law* 2020;45(3):419-437.

9. Torres MA, Gogineni K, Howard DH. Intensity-modulated radiation therapy in breast cancer patients following the release of a Choosing Wisely recommendation. *Journal of the National Cancer Institute* 2020;112(3):314-317.
10. Wilkinson S, Howard DH, Busch S. Psychiatric practice patterns and barriers to the adoption of esketamine. *Journal of the American Medical Association* 2019;322(11):1039-1040.
11. Howard DH, Hockenberry J. Physician age and the abandonment of episiotomy. *Health Services Research* 2019;54(3):650-657.
12. Howard DH. Trends in the use of knee arthroscopy in adults. *JAMA: Internal Medicine* 2018;178(11):1557-1558.
13. Merchant F, Dikert N, Howard DH. Mandatory shared decision making by CMS for cardiovascular procedures and other tests. *Journal of the American Medical Association* 2018;320(7):641-642.
14. David G, Berez J, Howard DH, Neuman M. Does bad news travel faster? On the determinants of medical technology abandonment. *Journal of Human Capital* 2018;12(4): 569-603.
15. Howard DH, Roback JD, Murphy DJ. Trends in transfusion rates after the FOCUS trial. *Journal of Comparative Effectiveness Research* 2018;7(2):113-120.
16. Howard DH, Hockenberry J, David G. Physicians' financial incentives to personalize medicine. in Berndt E, Goldman D, and Rowe J. *Economic Dimensions of Personalized and Precision Medicine*, 2018. (NBER Working Paper No. 24054) .
17. Schnier KE, Merion RM, Turgeon N, Howard DH. Subsidizing altruism in living organ donation. *Economic Inquiry* 2018;56(1):398-426.
18. Howard DH, Herring B, Graves J, Trish E. Provider-owned insurers in the individual market. *American Journal of Managed Care* 2018;24(12):e393-e398.
19. Howard DH, Trish E. Provider-owned insurers. *American Journal of Managed Care* 2017;23(9):566-567.
20. Melanson TA, Hockenberry JM, Plantinga L, Basu M, Pastan S, Mohan S, Howard DH, Patzer RE. New kidney allocation system associated with increased rates of transplants among black and Hispanic patients. *Health Affairs* 2017;36(6):1078-1085
21. Howard DH. Evidenced-based claims about evidence. *Medical Decision Making: Policy & Practice* 2017;2(2):2381468317734527.
22. Howard DH, David G, Hockenberry J. Selective hearing: physician-ownership and physicians' response to new evidence. *Journal of Economics and Management Strategy* 2017; 26(1):152-168.
23. Howard DH, Soulos PR, Chagpar AB, Mougalian S, Killelea B, Gross CP. Contrary to conventional wisdom, physicians abandoned a breast cancer treatment after a trial concluded it was ineffective. *Health Affairs* 2016;35(7):1309-1315.
24. Lyu PF, Hockenberry JM, Gaydos LM, Howard DH, Buchman TG, Murphy DJ. Impact of a sequential intervention on albumin utilization in critical care. *Critical Care Medicine* 2016;44(7):1307-1313.
25. Howard DH, Gross CP. Producing evidence to reduce low value care. *JAMA: Internal Medicine* 2015;175(12):1893-1894.

26. Howard DH, Bach P, Berndt ER, Conti R. Pricing in the market for anticancer drugs. *Journal of Economic Perspectives* 2015;29(1):139-162. *American Economic Association* "articles recommended for classroom use."
27. Smieliauskas, F, Lam S, Howard DH. Impact of negative clinical trial results for vertebroplasty on vertebral augmentation procedure rates. *Journal of the American College of Surgeons* 2014;219(3):525-533.
28. Howard DH. Adverse effects of prohibiting narrow provider networks. [Perspective] *New England Journal of Medicine* 2014;371(7):591-593.
29. Howard DH. Drug companies' patient-assistance programs--helping patients or profits? [Perspective] *New England Journal of Medicine* 2014;371(2):97-99.
30. Howard DH, Shen YC. Trends in PCI volume after negative results from the COURAGE trial. *Health Services Research* 2014;49(1):153-170.
31. Shen YC, Caughey A, Chung W, Howard DH. Can major systematic reviews influence practice patterns? A case study of episiotomy trends. *Archives of Gynecology and Obstetrics* 2013;288(6):1285-1293.
32. Howard DH, Tangka F, Ekwueme D, Guy G, Lipscomb J. Prostate cancer screening in men ages 75 and older fell by 8 percentage points after Task Force recommendation. *Health Affairs* 2013;32(3):596-602.
33. Howard DH, Brophy R, Howell S. Evidence of no benefit from knee surgery for osteoarthritis led to coverage changes and is linked to decline in procedures. *Health Affairs* 2012;31(10):2242-2249.
34. Howard DH. Declines in prostate cancer incidence after changes in screening recommendations. *Archives of Internal Medicine* 2012;172(16):1267-1268.
35. Howard DH, Adams EK. Mammography rates after the 2009 US Preventive Services Task Force breast cancer screening recommendation. *Preventive Medicine*. 2012;55(5):485-487.
36. Howard DH, Shen YC. Comparative effectiveness research, technological abandonment, and health care spending. *Advances in Health Economics and Health Services Research*. 2012; 23:103-121.
37. Howard DH, Kenline C, Hassebroek A, Horowitz MM, Parsons SK, Rizzo JD, Majhail NS. Abandonment of high dose chemotherapy/hematopoietic cell transplants for breast cancer. *Health Services Research* 2011;46(6):1762-1777.
38. Howard DH. Realigning incentives for developing and pricing new anticancer treatments. *Journal of the American Medical Association* 2011;305(22):2347-2348.
39. Howard DH, SH Busch, KE Thorpe. Understanding recent increases in chronic disease treatment rates: more diseases or more detection? *Health Economics, Policy and Law* 2010;5(4):411-435.
40. Howard DH. Comparative effectiveness research and cancer screening and in the US and Europe. *Medical Decision Making* 2009;29(6): NP12-NP13.
41. Howard DH, LC Richardson, KE Thorpe. The relationship between age and receipt of common cancer screening tests in the U.S. and Europe. *Health Affairs* 2009;28(6):1838-1848.

42. Howard DH, Meltzer D, Kollman C, Maiers M, Logan B, Gragert L, Setterholm M, Horowitz MM. Using cost-effectiveness analysis to design a national cord blood bank. *Medical Decision Making* 2008;28:243-253.
43. Thorpe KE, Howard DH, K Galactionova. Differences in disease prevalence as a source of the US-European health care spending gap. *Health Affairs* 2007;26(6): w678-w686.
44. Kakoli R, DH Howard. Equity in out-of-pocket payments for hospital care: evidence from India. *Health Policy* 2007;80(2):297-307.
45. Thorpe KE, DH Howard. The rise in Medicare spending: the role of chronic disease prevalence and changes in treatment intensity. *Health Affairs* 2006;25(5):w378-w388.
46. Thorpe KE, Howard DH. Health insurance and spending among cancer patients. *Health Affairs* 2003;W3:189-198.
47. Fernandez JM, Stohr L, Howard DH. The effect of cadaveric kidney donations on living kidney donations: an instrumental variables approach. *Economic Inquiry* 2013;51(3):1696-1714.
48. Howard DH. Waiting time as a price for deceased donor kidneys. *Contemporary Economic Policy* 2011;29(3):295-303.
49. Howard DH. Hospital quality and selective contracting: evidence from kidney transplantation. *Forum for Health Economics & Policy* 2008;11:Article 2.
50. Howard DH. Producing organ donors. *Journal of Economic Perspectives* 2007;21(3):25-36.
51. Howard DH, L Siminoff, V McBride, M Lin. Does quality improvement work? Evaluation of the Organ Donation Breakthrough Collaborative. *Health Services Research* 2007;42(6):2160-2173.
52. Howard DH, MM Byrne. Should we promote organ donor registries when so few registrants will end up being donors? *Medical Decision Making* 2007;27:243-249.
53. Howard DH. Life expectancy and the value of early detection. *Journal of Health Economics* 2005;24(5):891-906.
54. Howard DH. Quality and consumer choice in health care. Evidence from kidney transplantation. *B.E. Journals in Economic Analysis and Policy* 2005;5(1):Article 24.
55. Howard DH, B Kaplan. Do report cards influence hospital choice? The case of kidney transplantation. *Inquiry* 2006;43(2):150-159.
56. Howard DH. Why do transplant surgeons turn down organs? A model of the accept/reject decision. *Journal of Health Economics* 2002;21(6):931-1094.
57. Howard DH. Dynamic analysis of liver allocation policies. *Medical Decision Making* 2001;21(4):257-266.
58. Howard DH. Hope versus efficiency in liver allocation. *Transplantation* 2001;72(6):1169-1173.

Medicine and Public Health

59. Horny M, Yabroff KR, Filson CP, Zheng Z, Ekwueme DU, Richards TB, Howard DH. The cost burden of metastatic prostate cancer in the US populations covered by employer-sponsored health insurance. *Cancer* Forthcoming.

60. Dean NE, Howard DH, Lopman BA. Serological studies and the value of information. *American Journal of Public Health* Forthcoming.
61. Karakis I, Boulam N, Moura LMVR, Howard DH. Quality of life and functional limitations in persons with epilepsy. *Epilepsia* Forthcoming.
62. Olsen TA, Filson CP, Richards TB, Ekwueme DU, Howard DH. The cost of metastatic prostate cancer in the United States. *Urology Practice* Forthcoming.
63. Moura Lidia MVR, Karakis I, Zack MM, Tian N, Kobau R, Howard DH. Drivers of US healthcare spending for persons with seizures and/or epilepsies, 2010-2018. *Epilepsia* 2022;63(8):2144-2154.
64. Hersch Nicholas L, Davidoff AJ, Howard DH, Keating NL, Ritzwoller DP, Yabroff KR, Bradley CR. Cancer survivorship and supportive care economics research: current challenges and next steps. *Journal of the National Cancer Institute* 2022;2022(59):57-63.
65. Howard DH, Quek RGW, Fox KM, Arondekar B, Filson CP. The value of new drugs for advanced prostate cancer. *Cancer* 2021;127(18):3457-3465.
66. Liu Y, Hall IJ, Filson C, Howard DH. Trends in the use of active surveillance and treatments in Medicare beneficiaries diagnosed with localized prostate cancer. *Urologic Oncology* 2021;39(7):432.e1-432.e10.
67. Sanda M, Howard DH, Patil D, Filson CP. Disparities in prostate magnetic resonance imaging for traditionally underserved prostate cancer patients. *Cancer* 2021;127(16):2974-2979.
68. Tangka F, Kenny K, Miller J, Howard DH. The eligibility and reach of the National Breast and Cervical Cancer Early Detection Program after implementation of the Affordable Care Act. *Cancer Causes and Control* 2020;31:473-489.
69. Baker-Goering, MM, Howard DH, Roy K. Association between antihypertensive medication non-adherence and out-of-pocket costs among individuals aged 35–64 years with employer-sponsored health insurance in the United States, 2014. *Preventing Chronic Diseases* 2019;16:E32.
70. Baker-Goering, MM, Howard DH, Roy K. Association between self-reported hypertension and antihypertensive medication use, and adverse cardiovascular disease events and expenditures. *Public Health Reports* 2019;134(5):493-501.
71. Blake S, Howard DH, Hawley J, Henkel A. Implementation of Florida long term care emergency preparedness portal web Site, 2015–2017. *American Journal of Public Health* 2018;108(Suppl 5):S399–S401.
72. Liu W, Patil D, Howard DH, Moore R, Wang H, Sanda M, Filson CP. Adoption of pre-biopsy magnetic resonance imaging for men undergoing prostate biopsy in the United States. *Urology* 2018;117:57-63.
73. Zhang X, Melanson TA, Plantinga LC, Basu M, Pastan SO, Mohan S, Howard DH, Hockenberry JM, Garber MD, Patzer RE. Racial/ethnic disparities in waitlisting for deceased donor kidney transplantation one year after implementation of the new national kidney allocation system. *American Journal of Transplantation* 2018;18(8):1936-1946.
74. Chokshi FH, Howard DH, Jarvik JG, Duszak Jr R. Trends in vertebral augmentation for spinal fractures in myeloma patients: a 2002–2012 population-based study using a large national cancer registry *Journal of NeuroInterventional Surgery* 2018;10(2):183-190.

75. Ashraf HM, Davies BJ, Howard DH, Filson CP. Physician reimbursement for prostate biopsies falls as procedures shift from offices to facilities. *Urology* 2018;115:96-101.
76. Sanda MG, Feng Z, Howard DH, Tomlins SA, Sokoll LJ, Chan DW, Regan MM, Groskopf J, Chipman J, Patil DH, Salami SS, Scherr DS, Kagan J, Srivastava S, Thompson IM Jr, Siddiqui J, Fan J, Joon AY, Bantis LE, Rubin MA, Chinnayian AM, Wei JT; and the EDRN-PCA3 Study Group, Bidair M, Kibel A, Lin DW, Lotan Y, Partin A, Taneja S. Association Between Combined TMPRSS2:ERG and PCA3 RNA Urinary Testing and Detection of Aggressive Prostate Cancer. *JAMA Oncology* 2017;3(8):1085-1093.
77. Galvin JE, Howard DH, Denny SS, Dickinson S, Tatton N. The social and economic burden of frontotemporal degeneration. *Neurology* 2017;89(20):2049-2056.
78. Henry MA, Howard DH, Davies BJ, Filson CP. Variation in use of prostate biopsy following changes in prostate cancer screening guidelines. *Journal of Urology* 2017;198(5):1046-1053.
79. Kokabi N, Duszak R Jr, Xing M, Howard DH, Applegate KE, Camacho JC, Kim HS. Cancer-directed therapy and potential impact on survival in nonresected hepatocellular carcinoma: SEER-Medicare population study. *Future Oncology* 2017;13(23):2021-2033
80. Alexander VM, Gordon AN, Howard DH, Khanna N. Outcomes and cost analysis of surveillance strategies after initial treatment for women with recurrent ovarian cancer. *International Journal of Gynecological Cancer* 2017;27(7):1333-1342.
81. Howard DH, Chernew M, Abdelgawad T, Smith GL, Sollano J, Grabowski D. New anticancer drugs associated with large increases in costs and life expectancy. *Health Affairs* 2016;35(9):1581-1587.
82. Qin X, Tangka FKL, Guy GP, Howard DH. Mammography rates after the 2009 revision to the United States Preventive Services Task Force breast cancer screening recommendation. *Cancer Causes and Control*. 2017;28(1):41-48.
83. Kokabi N, Xing M, Duszak R Jr, Howard DH, Camacho JC, Kim HS. Sociodemographic disparities in treatment and survival of small localized renal cell carcinoma: surgical resection versus thermal ablation. *Journal of Comparative Effectiveness Research* 2016;5(5):441-452.
84. Patzer RE, Basu M, Larsen CP, Pastan SO, Mohan S, Patzer M, Konomos M, McClellan WM, Lea J, Howard D, Gander J, Jacob Arriola K. iChoose Kidney: a clinical decision aid for kidney transplantation vs. dialysis treatment. *Transplantation* 2016;100(3):630-639.
85. Yang Z, Howard DH, Will J, Loustalot F, Ritchey M, Roy K. Association of antihypertensive medication adherence with healthcare use and Medicaid expenditures for acute cardiovascular events. *Medical Care* 2016;54(5):504-511.
86. Kokabi N, Xing M, Jr RD, Howard DH, Applegate KE, Camacho JC, Kim HS. Sociodemographic impact on survival in unresectable hepatocellular carcinoma: a survival epidemiology and end results study. *Future Oncology* 2016;12(2):183-198.
87. Rai A, Nastoupil LJ, Williams JN, Lipscomb J, Ward KC, Howard DH, Lee D, Flowers CR. Patterns of use and survival outcomes of positron emission tomography for initial staging in elderly follicular lymphoma patients. *Leukemia Lymphoma* 2016: 1-11.

88. Asay GRB, Roy K, Lang JE, Payne RL, Howard DH. Absenteeism and employer costs associated with chronic diseases and health risk factors in the US workforce. *Preventing Chronic Diseases* 2016;13:150503.
89. Goldstein DA, Chen Q, Ayer T, Howard DH, Lipscomb J, Ramalingam SS, Khuri FR, Flowers CR. Necitumumab in metastatic squamous cell lung cancer: establishing a value-based cost. *JAMA Oncology* 2015;1(9):1293-1300.
90. Howard DH, Richards TB, Bach PB, Kegler M, Berg C. Comorbidities, smoking status, and life expectancy among persons eligible for lung cancer screening. *Cancer* 2015;121(24):4341-4347.
91. Howard DH, Tangka FK, Royalty J, Dalzell LP, Miller J, O'Hara B, Joseph K, Kenney K, Guy G, Hall IJ. Breast cancer screening of underserved women in the USA: results from the National Breast and Cervical Cancer Early Detection Program, 1998-2012. *Cancer Causes Control* 2015;26(5):657-68.
92. Tangka FK, Howard DH, Royalty J, Dalzell LP, Miller J, O'Hara BJ, Sabatino SA, Joseph K, Kenney K, Guy GP Jr, Hall IJ. Cervical cancer screening of underserved women in the United States: results from the National Breast and Cervical Cancer Early Detection Program, 1997-2012. *Cancer Causes Control* 2015;26(5):671-86
93. Goldstein DA, Ahmad BB, Chen Q, Ayer T, Howard DH, Lipscomb J, El-Rayes BF, Flowers CR. Cost-effectiveness analysis of regorafenib for metastatic colorectal cancer. *Journal of Clinical Oncology* 2015;33(32):3727-3732.
94. Tangka FKL, Subramanian S, Cabatino SA, Howard DH, Haber S, Hooer S, Richardson LC. End-of-life medical costs of Medicaid cancer patients. *Health Services Research* 2015;50(3):690-709.
95. Goede SL, Kuntz KM, van Ballegooijen M, Knudsen AB, Lansdorp-Vogelaar I, Tangka FK, Howard DH, Chin J, Zauber AG, Seeff LC. Cost-savings to Medicare from pre-Medicare colorectal cancer screening. *Medical Care* 2015;53(7):630-638.
96. Fernandez F, Gillespie TW, Pickens A, Force S, Khullar OV, Jiang R, Howard DH, Ward KC. Hospital readmission is associated with poor survival following esophagectomy for esophageal cancer. *Annals of Thoracic Surgery* 2015;99(1):292-297.
97. Goldstein DA, Flowers CR, Qiushi C, El-Rayes B, Ayer T, Howard DH, Lipscomb J. First and second line bevacizumab in addition to chemotherapy for metastatic colorectal cancer: A US based cost-effectiveness analysis. *Journal of Clinical Oncology* 2015;33(10):1112-1118.
98. Howard DH, Karcz A, Roback JD. The accuracy of claims data for measuring transfusion rates. *Transfusion Medicine* 2016;26(6):457-459.
99. Daugherty JD, Blake, SC, Grosholz, JM, Omer, SB, Polivska-West, L, Howard, DH. Influenza vaccination rates and beliefs among nursing home employees. *American Journal of Infection Control* 2015;43(2):100-106.
100. Zhang K, Howard DH. Hospital and skilled nursing facility patient flows during Hurricane Katrina and the Midwest Floods of 2008. *Health Systems* 2015;4:29-40.
101. Grosholz JM, Blake S, Daugherty JD, Ayers E, Omer SB, Polivka-West L, Howard DH. Accuracy of influenza vaccination rate estimates in United States nursing home residents. *Epidemiology and Infection* 2014;18:1-8.

102. Escoffery C, Rodgers KC, Haardörfer R, Howard D, Roland K, Castro G, Wilson K, Kegler MC. Key informant interviews of special events to increase cancer screening in the U.S. *Health Education Research* 2014;29(5):730-739.
103. Mohan A, Fazel R, Huang, PH, Shen, YC, Howard, DH. Changes in geographic variation in percutaneous coronary intervention (PCI) for stable ischemic heart disease following publication of the COURAGE trial. *Circulation: Cardiovascular Quality and Outcomes* 2014;7(1):125-130.
104. Goldstein DA, Chen Q, Ayer T, Howard DH, Lipscomb J, Harvey RD, El-Rayes BF, Flowers CR. Cost effectiveness analysis of pharmacokinetically guided 5-fluorouracil in FOLFOX chemotherapy for metastatic colorectal cancer. *Clinical Colorectal Cancer* 2014;13(4):219-225.
105. Klein IM, Boccia RV, Cannon E, Cardarelli WJ, Gamble B, House L, Howard DH, Malloy M, McAllister RD, Milota B, Rice G, Rice M. Evolving strategies for the management of multiple myeloma: a managed care perspective. *American Journal of Managed Care* 2014;20(2):s45-60.
106. Howard DH, Guy GP Jr, Ekwueme DU. Eliminating cost-sharing requirements for colon cancer screening in Medicare. *Cancer* 2014;120(24):3850–3852.
107. Escoffery C, Rodgers KC, Kegler MC, Haardörfer R, Howard DH, Liang S, Pinskar E. A systematic review of special events to promote breast, cervical and colorectal cancer screening in the United States. *BMC Public Health* 2014;14:274.
108. Halpern M, Romaire M, Haber S, Tangka F, Sabatino S., Howard DH. Impact of state-specific Medicaid reimbursement and eligibility policies on receipt of cancer screening. *Cancer* 2014;120(19):3016-3024.
109. Halpern M, Haber S, Sabatino S, Subramanian S, Howard, DH. Tangka FK. Cancer screening among U.S. Medicaid enrollees with chronic comorbidities or residing in long-term care facilities. *Journal of Analytic Oncology* 2013:98-106.E1-E20.
110. Howard DH. A better understanding of variation in cancer treatment [Invited editorial]. *Medical Care* 2012;50(5):363-365.
111. Subramanian S, Tangka F, Sabatino SA, Howard DH, Richardson LC, Haber S, Halpern M, Hoover S. Impact of chronic conditions on the cost of cancer care for Medicaid beneficiaries. *Medicare & Medicaid Research Review* 2012:2(4).
112. Howard DH, Huang Y. Serious health events and discontinuation of routine cancer screening. *Medical Decision Making* 2012;32(4):627-635.
113. Daugherty JD, Eiring H, Blake S, Howard DH. Disaster preparedness in home health and personal-care agencies: are they ready? *Gerontology* 2012;58(4):322-330.
114. Howard D, Zhang R, Huang Y, Kutner N. Hospitalization rates among dialysis patients during Hurricane Katrina. *Prehospital and Disaster Medicine* 2012;27(4):325-329.
115. Blake S, Eiring H, Howard DH. San Diego's Area Coordinator System: A disaster preparedness model for U.S. nursing homes. *Disaster Medicine and Public Health Preparedness* 2012;6(4):424-427.
116. Shaukat, A, Liff J, Lederle F, Salfiti N, Howard DH. Is Ulcerative Colitis associated with survival among older persons with colorectal cancer in the U.S? A population-based case-control study. *Digestive Diseases and Sciences* 2012;57(6):1647-1651.

117. Eiring H, Blake S, Howard D. Nursing homes' preparedness plans and capabilities. *American Journal of Disaster Medicine* 2012;7(2):127-135.
118. Shaukat A, Salfiti N, Virnig DJ, Howard DH, Sitaraman SV, Liff JM. Is inflammatory bowel disease an important risk factor among older persons with colorectal cancer in the US? A Population-Based Case-Control Study. *Digestive Diseases and Sciences* 2011;56(8):2378-2383.
119. Roblin D, Howard DH, Junling R, Becker N, Howard DH. An evaluation of primary care team functioning on the health of Medicare beneficiaries. *Medical Care Research & Review* 2011;68(2):177-201.
120. Tangka FK, Trogdon JG, Richardson LC, Howard DH, Sabatino SA, Finkelstein EA. Cancer treatment cost in the United States: Has the burden shifted over time? *Cancer* 2010;116(14):3477-3484.
121. Howard DH, Ekwueme DU, Gardner JH, Tankga FK, Li C, Miller JW. The impact of a national program to provide free mammograms to low income uninsured women on breast cancer mortality rates. *Cancer* 2010;116(19):4456-4462.
122. Howard DH, Kauh J, Lipscomb J. The value of new chemotherapeutics for metastatic colorectal cancer. *Archives of Internal Medicine* 2010;170(6):537-542.
123. Howard DH, Huang A, Adams EK. Discontinuation of screening mammography after serious health events. *Archives of Internal Medicine* 2009;169(22):2162-2163.
124. Howard DH, FK Tangka, LC Seeff, LC Richardson. The impact of detection and treatment on lifetime medical costs for patients with precancerous polyps and colorectal cancer. *Health Economics* 2009;18(12):1381-1393.
125. Wu JH, DH Howard, JE McGowan, Jr., RS Turpin, XH Hu. Adherence to Infectious Disease Society of America guidelines on empiric therapy for patients with community acquired pneumonia in a commercially insured cohort. *Clinical Therapeutics* 2006;28(9):1451-1461
126. Thorpe KE, DH Howard. The rise in Medicare spending: the role of chronic disease prevalence and changes in treatment intensity. *Health Affairs* 2006;25(5):w378-w388.
127. Howard DH, S Culler, B Druss. KE Thorpe. The impact of mortality risk on end of life costs. *Applied Health Economics and Health Policy* 2006;5(1):37-44.
128. Howard DH, T Sentell, JA Gazmararian. The impact of health literacy on socioeconomic and racial differences in health in an elderly population. *Journal of General Internal Medicine* 2006;21:857-861.
129. Howard DH, RD Scott. The economic burden of drug resistance. *Clinical Infectious Diseases* 2005;41:S283-S286.
130. Thorpe KE, CS Florence, DH Howard, P Joski. The rising prevalence of treated disease: effects on private health insurance spending. *Health Affairs* 2005;W5/317-W5/325.
131. Howard DH, JA Gazmararian, RM Parker. The impact of low health literacy on medical costs for Medicare managed care enrollees. *American Journal of Medicine* 2005;118:371-377.
132. Howard DH, NA Molinari, KE Thorpe. National estimates of medical costs incurred by non-elderly cancer patients. *Cancer* 2004;100(5):883-891.

133. Howard DH, K Roy. Private care and public health: do vaccination and prenatal care rates differ between users of private versus public sector care in India? *Health Services Research* 2004;39(6):2013-2026.
134. Wu JH, DH Howard, JE McGowan, Jr, LM Frau, WS Dai. Patterns of healthcare resource utilization after macrolide treatment failure: results from a large population based cohort with acute sinusitis, acute bronchitis and community-acquired pneumonia. *Clinical Therapeutics* 2004;26(12):2153-2162.
135. Thorpe KE, CS Florence, DH Howard, P Joski. The impact of obesity on rising medical costs. *Health Affairs* 2004;W4:480-486.
136. Howard DH. Resistance-induced antibiotic substitution. *Health Economics* 2004;13(6):585-595.
137. Roblin D, N Becker, K Adams, DH Howard, MH Roberts. Patient satisfaction with primary care: does practitioner type matter? *Medical Care* 2004;42(6):579-590.
138. Roblin D, DH Howard, K Adams, N Becker. Use of midlevel practitioners to achieve labor cost savings in the primary care practice of a MCO. *Health Services Research* 2004;39(3):607-626.
139. Howard DH, J McGowan Jr. The cost of antibiotic treatment failure among children with respiratory infections. *Pediatrics* 2004;113(5):1352-1356.
140. Howard DH, D Scott, R Packard, D Jones. The global impact of resistance. *Clinical Infectious Diseases* 2003;36(S1):S4-S11.
141. Howard DH. The effect of waiting time on liver transplant outcomes. *Health Services Research* 2000;35(5):1117-1134.

Working papers

Howard DH, M Horný, M Dillender. Fee cuts for radiology and low-value care. Under review.

Gruber J, DH Howard, J Leder-Luis, TL Caputi. Dying or lying? For-profit hospices and end of life care. National Bureau of Economic Research Working Paper 31035. Revise and resubmit at *American Economic Review*.

BOOK CHAPTERS

Howard DH, C Zeldin. Accountable care organizations. In Kronenfeld JJ, Parmet WE, Zezza MA, eds. *Debates on U.S. Health Care*. Los Angeles, CA: Sage; 2012.

Howard DH. Producing organ donors. In AV Menon, ed. *Organ Transplantation. Legal and Ethical Dimensions*. Icfai University Press, Hyderabad, India, 2009.

Howard DH. Patient and physician demand for antibiotics. In R Laxminarayan and A Malani, eds. *Extending the Cure: Policy Responses to the Growing Threat of Antibiotic Resistance* Washington DC: Resources For the Future; 2007.

Howard DH, M Maiers, L Gragert, M Setterholm, C Kollman, B Logan. The impact of cord blood inventory size on patient survival time and costs. In E Meyer, A Pope, eds. *Report on Establishing a National Cord Blood Stem Cell Bank Program* Washington, DC: ational Academies Press; 2005.

Scott D, R Roberts, R Cordell, Howard DH, J McGowan Jr, S Solomon. Measuring the attributable costs of resistant infections in hospital settings. In: RC Owens Jr., PG Ambrose, CH Nightingale, eds. *Antibiotic Optimization: Concepts and Strategies in Clinical Practice*. New York, NY: Marcel Dekker; 2005.

Howard DH. The Relationship between health literacy and medical costs. In: Institute of Medicine. LT Nielsen-Bohlman, AM Panzer, B Hamlin, DA Kindig, eds. *Health Literacy: A Prescription to End Confusion* Committee on Health Literacy, Board on Neuroscience and Behavioral Health. Washington, DC: National Academies Press; 2004.

Howard DH, K Rask. Antibiotic resistance and antibiotic demand. In R Laxminarayan ed. *Battling Resistance to Antibiotics and Pesticides* Washington, DC: Resources For the Future; 2002.

BOOK REVIEWS

Review of Kovner AR and Knickman JR, eds., Jonas & Kovner's Health Care Delivery in the United States. *Journal of the American Medical Association* 2012;307(23):2547-2547.

Review of Daniels, N. Just Health. *Journal of the American Medical Association* 2008;299(21):2568-2569.

Review of Barr, DA. Introduction to U.S. Health Policy. The Organization, Financing, and Delivery of Health Care in America. *Journal of the American Medical Association* 2007;299(1):99-100.

Review of Neumann, P. Using Cost-Effectiveness Analysis to Improve Health Care. *Journal of the American Medical Association* 2006;295:943-944.

EDITORIALS/BLOG POSTS

Allowing Public Payers to Base Coverage on a Drugs' Value is an Effective Way to Cut Prices. *The Hill* December 19, 2017.

Insurers Can Reduce Drug Prices, If Policymakers Let Them. *Health Affairs Blog* July 14, 2016.

Conservatives Hit the Wrong Health Care Reform Target. *The Atlanta Journal-Constitution* August 31, 2009.

Paying for the ACA: A Field Guide. *The Health Care Blog* October 12, 2013.
<http://thehealthcareblog.com/blog/2013/10/12/paying-for-the-aca-a-field-guide/>

FUNDING

Principal Investigator. Quantifying the burden of epilepsy using novel data sources Centers for Disease Control and Prevention. Special Interest Project 20-007, 2020-2024. \$1,508,482.

Principal Investigator. Updated Estimates of the Burden of Metastatic Prostate Cancer in Light of New Treatments and Recent Incidence Trends. Centers for Disease Control and Prevention. Special Interest Project 19-009, 2020-2022, \$766,024.

Principal Investigator. The Social Value of Anticancer Drugs for Prostate Cancer. Pfizer. 2019-2020, \$150,000.

Co-Investigator. Evaluating the impact of decision aid timing on mandatory shared decision making for defibrillator implantation. Emory Woodruff Health Sciences Center Synergy Awards. 2018-2019. \$100,000.

Principal Investigator, Understanding Hospitals' Responses to Mandatory Shared Decision Making, AHRQ, R03HS026578-01, 2018-2019, \$100,000.

Principal Investigator, Targeted Payment Cuts to Reduce Unproven Care, NIH/NCI, R01CA208758-01A1, 2017-2020, \$884,454.

Principal Investigator, Provider-led Plans and Insurance Affordability, Robert Wood Johnson Foundation, 73800, 2016-2017, \$86,825.

Principal Investigator, Measuring the Impact of Evidence on Blood Transfusion Rates, R03HS24613-01, AHRQ, 2016-2016, \$100,000.

Principal Investigator, Social Value of Cancer Drugs, Pfizer, 2014-2015. \$70,000.

Principal Investigator, Evaluation of Accountable Care Units, R03 HS 022595-01, AHRQ, 2013-2014. \$100,000.

Co-investigator, Impact of Volume and Temporal Distance on the Value of Organ Transplant Surgery, R03 HS 21789 – 01, AHRQ, 2012-2013. \$100,000.

Co-Investigator, Promoting Public Health Priorities Through Policy Analysis, 1U58CD001368-01, CDC, 2011-2012, \$73,367.

Principal Investigator, An Evaluation of Vaccination Practices of Nursing Home Residents and Staff, 1U01IP000411-01. CDC, 2010-2012, \$280,000.

Principal Investigator, Improving disaster planning in nursing homes, home health agencies, and dialysis centers (funded as a component of P01TP000300-01, Emory Preparedness and Emergency Response Research Center, Ruth Berkelman, Principal Investigator), CDC, 2009-2014, \$1,574,124.

Principal Investigator, Life expectancy and cancer screening, American Cancer Society, 2005-2010, \$610,934.

Co-Principal Investigator, Addressing health disparities among Georgians: focus on health literacy, Healthcare Georgia Foundation, 2004-2005, \$109,000.

Principal Investigator, The impact of outcomes on transplant center choice, NIDDK/NIH R21 DJ067611-01, 2004-2005, \$76,500.

Principal Investigator, A medical decision making approach to prostate cancer treatment, Georgia Cancer Coalition, 2003-2004, 38,742.

Co-Principal Investigator, The relationship between health literacy and medical costs, Pfizer Foundation, 2002-2003, \$38,000.

Co-Principal Investigator, Measuring the costs of a cancer carve-out, The Commonwealth Fund, 2002-2003, \$146,565.

TEACHING EXPERIENCE

Introduction to Health Policy (Undergraduate). Emory College, Emory University, 2015-Present.

Policy Analysis (Graduate, MPH). Rollins School of Public Health, Emory University. 2002-Present.

Doctoral seminar in health economics. Rollins School of Public Health and Department of Economics, Emory University, 2006-2009.

Introduction to the U.S. health care system (Graduate, MPH). Rollins School of Public Health, Emory University. 2001-2006.

DISSERTATION COMMITTEES

Manasvini Singh (Health Policy, 2020), The Role of Informational Environments in Physician Decision-Making.

Jae Eui Soh (Biostatistics, 2019), Dynamic Regression with Recurrent Events.

Blake McGee (Nursing, 2018), Prescription Drug Spending and Medication Adherence in Heart Failure.

Xin Yan (Economics, 2018), Responding to Negative Product Shocks: Evidence from the Relabeling of Pharmaceuticals in the United States

Zhuo Yang (Health Policy, 2018), Impact of the Medicaid Fee Bump.

Shang Ji (Biostatistics, In Progress), Quantile Regression for Complex Censored Data.

Ashish Rai (Health Policy, 2015). Follicular Lymphoma in the Medicare Population: Determinants and Outcomes of Management Approaches.

Kenton Johnson (Health Policy, 2015). More Doctors, Better Care? Patient and Physician Inputs, Outputs, and Outcomes of the Clinical Evaluation and Management Process for Medicare Beneficiaries with Chronic Conditions.

Maria Aslam (Economics, 2014). Economics of Precautionary Messages: Labeling Health Risks.

Jennifer Grant (Chair, Health Policy, 2013) Trends in HPV Vaccination of US Adolescent Females: How Policies, Education, and Health Care Providers Influence Immunization Rates.

Joseph Njau (Health Policy, 2013). Essays on the Economic and Social-Behavioral Effectiveness of Large Scale Malaria Control Programs in Three Sub-Saharan Africa Countries.

Ya-lin (Aileen) Huang (Chair, Health Policy, 2010), Three Essays on Births after Cesarean Section. Winner: Outstanding Achievement in Healthcare Student Research Using HCUP Data (AHRQ).

Deliana Kostova (Economics, 2010), Essays on Global Tobacco Use: The Role of Cigarette Prices and Regulation.

Lydia Ogden (Health Policy, 2010), The Impact of Federalism on U.S. Health Policy Formulation, Implementation, and Evaluation.